We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02437500
Expanded Access Status : Available
First Posted : May 7, 2015
Last Update Posted : February 8, 2023
Information provided by (Responsible Party):
Seres Therapeutics, Inc.

Brief Summary:
Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days. The purpose of this study is to provide access to SER-109 for adult subjects with recurrent Clostridioides Difficile Infection (RCDI) and to monitor subject safety and report to regulatory authorities, as appropriate.

Condition or disease Intervention/treatment
Clostridioides Difficile Infection Biological: SER-109

Detailed Description:

SERES-016 is a multicenter, expanded-access program (EAP) of SER-109 for subjects with RCDI conducted in the US. Up to approximately 90 subjects are expected to be treated with SER-109, or until SER-109 investigational product is exhausted. Within 3 days after end of antibiotics and on the day preceding SER-109, a bowel cleanse should be administered.

Subjects who meet all the inclusion criteria and none of the exclusion criteria are eligible for participation in the EAP. Each subject (or subject's legally authorized representative) will have to sign an informed consent form (ICF) indicating their consent to participate in the EAP.

Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)

Resource links provided by the National Library of Medicine

Intervention Details:
  • Biological: SER-109
    SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
    Other Name: Eubacterial Spores, Purified Suspension, Encapsulated

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  1. Signed informed consent prior to initiation of any EAP-specific procedure or treatment. The subject, or their legally authorized representative, must be willing to provide written informed consent and understand the potential risks and benefits from EAP enrollment and treatment.
  2. ≥2 episodes of CDI inclusive of the current episode
  3. The CDI recurrence must have met the protocol definition of:

    1. ≥3 unformed stools per day for 2 consecutive days
    2. A positive C. difficile stool toxin assay or PCR test
    3. CDI antibiotic therapy defined as either 10-21 days of vancomycin (125 mg po QID) or fidaxomicin (200 mg po BID). Pulse taper courses are also accepted.
    4. An adequate clinical response to antibiotic therapy, defined as (<3 unformed stools in 24 hours) for 2 or more consecutive days while on antibiotics.
    5. The requirement that the subject can be dosed with study drug within 4 days of antibiotic completion.

Main Exclusion Criteria:

  1. Female subjects who are pregnant, breastfeeding, lactating, or planning to become pregnant during the study.
  2. Known or suspected toxic megacolon and/or known small bowel ileus.
  3. Admitted to or expected to be admitted to an intensive care unit.
  4. Absolute neutrophil count of <500 cells/mm^3.
  5. Major gastrointestinal surgery (e.g., significant bowel resection or diversion) within 3 months before enrollment (this does not include appendectomy or cholecystectomy), or any history of total colectomy or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e., restrictive procedures such as banding, are permitted).
  6. History of active inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic colitis) with diarrhea believed to be caused by active inflammatory bowel disease in the past 3 months.
  7. Any history of fecal microbiota transplantation (FMT) in the past 3 months.
  8. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (subjects on maintenance chemotherapy may only be enrolled after consultation with the study medical monitor).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02437500

Layout table for location contacts
Contact: Kerri O'Dette 617-945-9626 kodette@serestherapeutics.com
Contact: ICON STUDY-ICO-3647-0014@iconplc.com

Sponsors and Collaborators
Seres Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Seres Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02437500    
Other Study ID Numbers: SERES-016
First Posted: May 7, 2015    Key Record Dates
Last Update Posted: February 8, 2023
Last Verified: February 2023
Keywords provided by Seres Therapeutics, Inc.:
Clostridioides Difficile Infection
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Gram-Positive Bacterial Infections
Communicable Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Clostridium Infections
Disease Attributes
Pathologic Processes
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses